|Day's Range||41.24 - 41.61|
|52 Week Range||37.03 - 54.73|
|PE Ratio (TTM)||37.16|
|Dividend & Yield||0.30 (0.72%)|
|1y Target Est||N/A|
The pharmaceutical business is a love-hate affair. Right now, Wall Street is feeling the latter for Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA). Although the Israeli pharma is one of the most respected names in the industry, TEVA stock plays the opposite role.
Amgen’s (AMGN) Xgeva was launched commercially in 2010 and is marketed primarily in the US and Europe. The drug crossed the $1 billion annual revenue mark in 2013.
Dr. Reddy's Laboratories Ltd. (RDY) reported fourth-quarter fiscal 2017 earnings per American Depositary Share (ADS) of 29 cents, down from 7 cents in the year-ago quarter.